Russell Investments Group Ltd. Lowers Stock Position in United Therapeutics Corporation $UTHR

Russell Investments Group Ltd. trimmed its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 25.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,712 shares of the biotechnology company’s stock after selling 15,942 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.11% of United Therapeutics worth $13,671,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Nuveen LLC purchased a new stake in shares of United Therapeutics in the first quarter valued at about $83,533,000. Amundi increased its position in United Therapeutics by 198.8% during the first quarter. Amundi now owns 350,193 shares of the biotechnology company’s stock worth $107,635,000 after buying an additional 232,988 shares in the last quarter. Assetmark Inc. raised its holdings in United Therapeutics by 38.1% in the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after acquiring an additional 197,384 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of United Therapeutics during the 2nd quarter valued at about $55,746,000. Finally, Acadian Asset Management LLC boosted its holdings in shares of United Therapeutics by 1,657.8% in the 1st quarter. Acadian Asset Management LLC now owns 179,205 shares of the biotechnology company’s stock valued at $55,217,000 after purchasing an additional 169,010 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Trading Down 1.2%

Shares of NASDAQ UTHR opened at $479.95 on Tuesday. The firm’s 50-day moving average is $448.96 and its 200-day moving average is $363.80. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $492.62. The firm has a market capitalization of $20.67 billion, a PE ratio of 18.19, a price-to-earnings-growth ratio of 4.96 and a beta of 0.77.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same quarter last year, the firm earned $6.39 EPS. United Therapeutics’s quarterly revenue was up 6.8% compared to the same quarter last year. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $400.56, for a total value of $9,012,600.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders have sold 556,935 shares of company stock valued at $244,015,177. Company insiders own 10.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on UTHR. Oppenheimer upped their target price on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Wells Fargo & Company upped their price target on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Jefferies Financial Group reaffirmed a “buy” rating and set a $575.00 price target on shares of United Therapeutics in a report on Wednesday, November 19th. HC Wainwright boosted their price objective on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Finally, UBS Group lifted their price target on United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.